Evenity (Romosozumab) Complete Drug-Drug Interaction Profile

Import from '@/components/mdx'

What Is Romosozumab and How Does It Work?

Romosozumab is a humanized monoclonal antibody that targets sclerostin, a protein produced almost exclusively by osteocytes (the long-lived bone cells embedded in mineralized tissue). By blocking sclerostin, romosozumab does something no other approved osteoporosis drug does: it simultaneously increases bone formation and decreases bone resorption. This dual action is sometimes called the "anabolic window," and it is the reason the drug produces rapid gains in bone mineral density that exceed what any antiresorptive drug achieves in 12 months.

Sclerostin normally binds to LRP5/6 co-receptors on osteoblast surfaces and suppresses the Wnt signaling pathway, which is the main driver of new bone formation. Romosozumab blocks that brake, releasing Wnt signaling and allowing osteoblasts to proliferate and lay down new bone matrix. The molecule simultaneously suppresses RANKL, reducing osteoclast-driven resorption. No other FDA-approved osteoporosis therapy achieves both effects at the same time.

Why This Mechanism Matters for Drug Interactions

Because romosozumab acts on a bone-specific signaling pathway rather than a broadly expressed enzyme system, it does not compete with or alter the metabolism of other medications the way a small-molecule drug might. The clinical consequence is that there are no formal pharmacokinetic drug-drug interactions on the romosozumab label. A woman taking statins, blood pressure medications, thyroid hormone, or most common prescriptions does not need dose adjustments for those drugs when starting Evenity.

The interactions that matter are pharmacodynamic. They occur when two drugs affect the same biological endpoint (bone, calcium, or cardiovascular risk), not when they share a metabolic pathway.

Pharmacokinetics: Why CYP Interactions Don't Apply

Romosozumab is a large-molecule biologic (molecular weight approximately 120 kDa). Like all therapeutic monoclonal antibodies, it is cleared by receptor-mediated endocytosis and nonspecific proteolysis, not by hepatic cytochrome P450 enzymes. It does not induce or inhibit CYP1A2, CYP2C9, CYP2C19, CYP2D6, or CYP3A4. It is not a substrate for P-glycoprotein or organic anion transporters.

Peak serum concentration occurs approximately 5 days after a 210 mg subcutaneous injection, and the estimated half-life is roughly 6.9 days. By the time the next monthly dose is due, serum levels are low but pharmacodynamic bone effects persist. This PK profile means renal or hepatic impairment does not require dose adjustment, and there is no interaction with drugs that affect drug-metabolizing enzymes.

The Complete Pharmacodynamic Interaction Profile

Pharmacodynamic interactions with romosozumab fall into four categories: cardiovascular risk amplification, calcium homeostasis disruption, bone-active drug sequencing effects, and immunosuppression overlap.

Category 1: Cardiovascular Risk Amplification

The FDA added a black-box warning to romosozumab in April 2019 after the ARCH trial showed that the romosozumab arm had a higher rate of serious cardiovascular events (myocardial infarction, stroke, cardiovascular death) compared with the alendronate arm during the active treatment year. The absolute difference was small (2.5% vs 1.9% in ARCH), but the signal was statistically significant enough to drive regulatory action.

For women who are already on medications that carry cardiovascular risk, this interaction demands explicit clinical discussion before prescribing:

NSAIDs and COX-2 inhibitors. Chronic NSAID or celecoxib use independently increases cardiovascular event risk, particularly in women with established coronary artery disease or peripheral arterial disease. The combination of NSAID-related vasoconstriction and platelet effects with romosozumab's observed cardiovascular signal represents an additive pharmacodynamic risk, though no direct interaction study exists for this pair. Women using NSAIDs long-term for rheumatoid arthritis or chronic pain should have their cardiovascular risk formally reassessed before starting romosozumab.

Immunomodulators used in inflammatory arthritis. Women with rheumatoid arthritis-related osteoporosis (a common clinical scenario, since RA affects women three times more than men) may be on JAK inhibitors such as tofacitinib or baricitinib. These drugs carry their own FDA cardiovascular black-box warnings. No formal interaction study covers romosozumab plus a JAK inhibitor, but prescribing both in a woman with existing cardiovascular risk factors is a scenario that warrants specialist co-management.

Hormone therapy. Menopausal hormone therapy (MHT) with estrogen-progestogen combinations is associated with a modest increase in cardiovascular events in older postmenopausal women, based on the Women's Health Initiative trial. Using MHT alongside romosozumab is not contraindicated by either drug's label, but a woman who is more than 10 years past her last period and taking both agents should have her cardiovascular risk factors (lipids, blood pressure, smoking history) reviewed.

Category 2: Calcium Homeostasis Disruption

Romosozumab markedly stimulates bone formation. This process consumes calcium rapidly, and hypocalcemia is identified as a contraindication in patients with pre-existing hypocalcemia. Drugs that independently lower serum calcium or impair calcium absorption can amplify this effect:

Loop diuretics (furosemide, bumetanide, torsemide). Loop diuretics increase urinary calcium excretion. A woman on furosemide for heart failure or edema who starts romosozumab is at real risk of clinically significant hypocalcemia. Serum calcium and 25-hydroxyvitamin D should be checked and corrected before the first injection.

Bisphosphonates used before romosozumab. This is less a toxicity interaction and more a sequencing interaction. Women who have been on long-term bisphosphonate therapy (particularly alendronate or zoledronic acid for more than 5 years) have suppressed osteoclast activity and a blunted remodeling rate. The STRUCTURE trial (NEJM 2017) demonstrated that women switching from teriparatide to romosozumab gained more hip BMD than women switching from alendronate to romosozumab, suggesting prior bisphosphonate exposure may partially dampen romosozumab's anabolic signal at cortical sites.

Proton pump inhibitors (omeprazole, esomeprazole, pantoprazole). PPIs reduce gastric acid and impair calcium carbonate absorption. Long-term PPI use independently increases fracture risk. A woman on a PPI alongside romosozumab should use calcium citrate (which does not require acid for absorption) rather than calcium carbonate, and her vitamin D level should be optimized before treatment begins.

Anticonvulsants (phenytoin, carbamazepine, phenobarbital). These are potent CYP3A4 inducers and independently accelerate catabolism of vitamin D to inactive metabolites, causing functional vitamin D deficiency and secondary hyperparathyroidism. This amplifies the calcemic demand romosozumab places on the body. Women with epilepsy on enzyme-inducing anticonvulsants need higher vitamin D replacement doses and close monitoring of serum calcium throughout the romosozumab course. Levetiracetam and lamotrigine do not share this enzyme-inducing effect and are safer from a calcium perspective.

Glucocorticoids. Prednisone and other glucocorticoids suppress osteoblast function, impair intestinal calcium absorption, increase urinary calcium losses, and cause secondary hyperparathyroidism. Women on chronic glucocorticoid therapy (prednisone 5 mg/day for 3 or more months) are a primary population for romosozumab consideration, yet the drugs work somewhat at cross-purposes at the bone level. The American College of Rheumatology guideline for glucocorticoid-induced osteoporosis identifies romosozumab as an option for very high fracture risk patients. Calcium 1,000 to 1,200 mg daily and vitamin D 800 to 1,000 IU daily are mandatory co-administration; without them, serum calcium instability becomes a real clinical risk.

Category 3: Sequential Bone-Active Drug Interactions

Romosozumab is approved for exactly 12 monthly doses. What comes after is not optional.

The romosozumab-to-antiresorptive sequence. The ARCH trial randomized women to romosozumab followed by alendronate versus alendronate alone. At 24 months (12 months of romosozumab plus 12 months of alendronate), the romosozumab-then-alendronate sequence reduced new vertebral fractures by 48% and hip fractures by 38% versus alendronate alone. This demonstrates that the anabolic gains from romosozumab are preserved and extended by antiresorptive therapy. Stopping romosozumab without transitioning to an antiresorptive causes rapid reversal of BMD gains, sometimes within 12 months.

Teriparatide before romosozumab. This sequence is actively discouraged. The FDA label notes that the clinical significance of combining anabolic agents has not been established, and the FRAME-EXTEND data showed attenuated hip BMD gains when patients had previously used teriparatide. Do not layer these two agents consecutively in a way that has not been studied.

Denosumab used concurrently. No trial has studied romosozumab and denosumab given simultaneously. Both affect RANKL biology (romosozumab indirectly, denosumab directly), and combining them would not be evidence-based practice.

The WomanRx Sequencing Framework for Postmenopausal Osteoporosis:

| Risk category | First-line | After 12 months | |---|---|---| | High fracture risk, no prior CV event, no prior bisphosphonate | Romosozumab 12 doses | Transition to denosumab or zoledronic acid | | Very high fracture risk with recent bisphosphonate use | Consider teriparatide first, then reassess | Romosozumab or bisphosphonate | | High fracture risk plus prior MI or stroke | Romosozumab generally avoided; use bisphosphonate or denosumab | Continue antiresorptive | | Glucocorticoid-induced osteoporosis, very high risk | Romosozumab is an ACR option with close calcium monitoring | Oral bisphosphonate |

Category 4: Immunosuppression Overlap and Biologic Combination

Romosozumab is an immunoglobulin G2 (IgG2) subclass monoclonal antibody. It does not directly suppress T-cell or B-cell function, so it does not carry the infection risk profile of agents like rituximab or abatacept. No contraindication exists for concurrent use with biologic DMARDs used in rheumatoid arthritis or psoriasis (adalimumab, etanercept, secukinumab) based on pharmacodynamic reasoning, though formal co-administration studies are absent from the literature. Women on these biologics who need romosozumab for RA-related osteoporosis should discuss the gap in co-administration data with their rheumatologist.

Live vaccines should not be given concurrently with romosozumab as a general biologic precaution, though the evidence for this specific agent is extrapolated from monoclonal antibody class effects rather than romosozumab-specific immunogenicity data.

Pregnancy, Lactation, and Contraception

Romosozumab is contraindicated in pregnancy. This must be stated plainly: no woman who is pregnant or planning pregnancy should receive this drug.

Animal reproductive studies showed fetal harm at doses lower than the human therapeutic dose. In cynomolgus monkeys, romosozumab caused stillbirth and neonatal death at exposures below the human clinical exposure level. The mechanism is not surprising: Wnt/LRP5 signaling is critical for fetal skeletal development. Blocking sclerostin during fetal bone formation would be expected to disrupt normal limb and axial skeletal patterning.

The drug's half-life of approximately 6.9 days means that by 6 to 8 weeks after the last dose, serum levels are negligible. Women who complete a 12-dose course and then wish to conceive should discuss timing with their clinician; the pregnancy itself is a separate conversation, since romosozumab is indicated for postmenopausal osteoporosis and its use in premenopausal women or women of reproductive age is off-label and not established.

Lactation. No data exist on romosozumab transfer into human breast milk. IgG antibodies do transfer into breast milk, though systemic absorption by the nursing infant is low because gastric acid and intestinal proteases degrade large proteins. The FDA label states that the developmental and health benefits of breastfeeding should be considered alongside the mother's clinical need, but because this drug is indicated for postmenopausal women, lactation is not a practical clinical scenario in labeled use. If a premenopausal woman were prescribed romosozumab off-label, breastfeeding would not be recommended given the absence of safety data.

Contraception. Women of reproductive age receiving romosozumab off-label (for premenopausal osteoporosis or other investigational indications) should use effective contraception during treatment and for at least one month after the last dose, based on the drug's half-life.

Who Is a Candidate and Who Is Not, by Life Stage

Postmenopause: The Primary Population

Romosozumab is approved specifically for postmenopausal women with osteoporosis at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture, or who have failed or are intolerant to other available osteoporosis therapy. This is the only life stage where the drug has regulatory approval and substantial trial data.

Approximately 54% of postmenopausal women in the United States have low bone mass or osteoporosis at the femoral neck or lumbar spine, and the first 5 to 7 years after the final menstrual period carry the steepest rate of bone loss, averaging 1 to 3% per year at the hip. For women in this window who have already fractured or have a T-score of -2.5 or below plus additional risk factors, romosozumab represents the fastest available path to substantial BMD recovery.

Perimenopause: Not Indicated

Romosozumab has no approved indication in perimenopausal women. Bone loss does begin during perimenopause as estradiol levels become erratic, but this phase is better managed by optimizing calcium, vitamin D, weight-bearing exercise, and, where appropriate, menopausal hormone therapy. Romosozumab's cardiovascular signal makes it a disproportionate risk in women who may have decades of cardiovascular life ahead of them.

Premenopausal Osteoporosis: Evidence Gap

Premenopausal women with severe osteoporosis (secondary to anorexia nervosa, glucocorticoid use, hypogonadism, or other causes) represent an area where the evidence is genuinely thin. The FRAME trial enrolled only postmenopausal women, and no large randomized controlled trial has evaluated romosozumab safety or efficacy in premenopausal women. Use in this group is off-label and should be managed at a center with experience in metabolic bone disease.

Women With Prior Cardiovascular Events: Avoid

The FDA label states that romosozumab should not be used in women who have had a myocardial infarction or stroke within the preceding year, and extreme caution is warranted in those with a history of any prior cardiovascular event. The American Society for Bone and Mineral Research position on the ARCH cardiovascular signal emphasizes individualized risk-benefit discussion. For a woman with a T-score of -3.2 and a vertebral compression fracture who also had a transient ischemic attack two years ago, the fracture risk may still outweigh cardiovascular risk, but this requires explicit shared decision-making with cardiology input.

Monitoring, Calcium, and Vitamin D: The Practical Interaction Most Often Missed

The most clinically important pharmacodynamic interaction in everyday practice is between romosozumab and inadequate calcium or vitamin D supplementation. This is not an exotic drug-drug interaction; it is the interaction most likely to cause a preventable adverse event.

All patients receiving romosozumab must be adequately supplemented with calcium and vitamin D before and during treatment. The label specifies at least 500 mg elemental calcium and 400 IU vitamin D daily, though most bone health guidelines recommend 1,000 to 1,200 mg calcium from combined diet and supplement sources and 800 to 2,000 IU vitamin D3 daily for postmenopausal women.

A woman whose 25-hydroxyvitamin D level is below 30 ng/mL before her first injection faces a real risk of symptomatic hypocalcemia (muscle cramps, perioral tingling, fatigue, in severe cases cardiac arrhythmia) as newly stimulated osteoblasts consume calcium rapidly. The Endocrine Society guideline for vitamin D deficiency recommends repletion to at least 30 ng/mL before initiating potent bone-anabolic therapy.

Check a serum 25(OH)D, comprehensive metabolic panel, and PTH before the first injection. Repeat calcium at each monthly visit or at minimum at the 3-month and 6-month marks. If a woman is also on a loop diuretic or a PPI, calcium monitoring at every injection visit is reasonable.

The Evidence Gap: What We Don't Know

Women have been historically underrepresented in cardiovascular drug trials, but in osteoporosis research, women actually constitute the primary trial population. The gap here is different: it is a gap in subgroup-specific interaction data.

Formal drug-drug interaction studies for romosozumab have not been published for the following clinically common combinations:

• Romosozumab plus SGLT-2 inhibitors (which cause urinary glucose loss and may affect bone turnover markers)
• Romosozumab plus aromatase inhibitors (which cause bone loss in women with hormone receptor-positive breast cancer and represent a population with severe osteoporosis at relatively young ages)
• Romosozumab plus JAK inhibitors in women with RA-related osteoporosis

"For women on aromatase inhibitors who have already experienced an osteoporotic fracture, romosozumab represents a mechanistically compelling option, but we are extrapolating from the ARCH and FRAME populations, which excluded most oncology patients. The cardiovascular signal is the added complication, because aromatase inhibitor patients already carry elevated cardiovascular risk from estrogen deprivation," notes Rachel Goldberg, MD, WomanRx Medical Director and author of this article. Clinicians managing this combination should involve both oncology and bone health specialists before prescribing.

The combination of romosozumab and SGLT-2 inhibitors (empagliflozin, dapagliflozin, canagliflozin) is another unstudied area. SGLT-2 inhibitors increase urinary calcium excretion and have mixed effects on bone turnover markers. Canagliflozin carried a fracture signal in early trials, though later meta-analyses were less consistent. A postmenopausal woman with type 2 diabetes on an SGLT-2 inhibitor who is starting romosozumab should have baseline and follow-up bone turnover markers and close calcium monitoring.

Practical Checklist Before the First Romosozumab Injection

1. Confirm no cardiovascular event (MI, stroke) in the past year.
2. Check serum 25(OH)D. Replete to at least 30 ng/mL before injection.
3. Check serum calcium. Correct any hypocalcemia before proceeding.
4. Review all concurrent medications for calcium-wasting effects (loop diuretics, enzyme-inducing anticonvulsants, PPIs, glucocorticoids).
5. Ensure a calcium plus vitamin D supplement plan is in place (target 1,000 to 1,200 mg calcium and at least 800 IU vitamin D3 daily from all sources).
6. Confirm no pregnancy and that effective contraception is in use if there is any reproductive potential.
7. Document the plan for antiresorptive therapy after month 12. The transition should be scheduled before the first injection, not after the last one.
8. For women on JAK inhibitors, biologic DMARDs, or aromatase inhibitors, obtain specialist co-sign before initiating.